Foghorn Therapeutics

Foghorn Therapeutics is a Cambridge, Massachusetts company targeting the chromatin regulatory system through its Gene Traffic Control platform. Its most advanced programme, FHD-909 (LY4050784), is a selective SMARCA2 ATPase inhibitor in phase 1 for SMARCA4-mutant non-small cell lung cancer, partnered with Lilly under a 50/50 US economic split with ex-US royalties; the Lilly collaboration also covers a selective SMARCA2 degrader and other programmes. Wholly owned preclinical programmes include a selective EP300 degrader for multiple myeloma, DLBCL and prostate cancer (IND targeted in 2027), a selective CBP degrader for ER-positive breast cancer, and a selective ARID1B degrader for ARID1A-mutant cancers. Foghorn also signed a collaboration with Merck in July 2020 (15 million US dollars upfront). Foghorn raised 135.2 million US dollars gross in its October 2020 Nasdaq IPO.